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Background: Cell therapy is a potential therapeutic approach for several neurodegenetative disease, including
Huntington Disease (HD). To evaluate the putative efficacy of cell therapy in HD, most studies have used excitotoxic
animal models with only a few studies having been conducted in genetic animal models. Genetically modified
animals should provide a more accurate representation of human HD, as they emulate the genetic basis of its
etiology.
Results: In this study, we aimed to assess the therapeutic potential of a human striatal neural stem cell line
(STROC05) implanted in the R6/2 transgenic mouse model of HD. As DARPP-32 GABAergic output neurons are
predominately lost in HD, STROC05 cells were also pre-differentiated using purmorphamine, a hedgehog agonist, to
yield a greater number of DARPP-32 cells. A bilateral injection of 4.5x105 cells of either undifferentiated or
pre-differentiated DARPP-32 cells, however, did not affect outcome compared to a vehicle control injection. Both
survival and neuronal differentiation remained poor with a mean of only 161 and 81 cells surviving in the
undifferentiated and differentiated conditions respectively. Only a few cells expressed the neuronal marker Fox3.
Conclusions: Although the rapid brain atrophy and short life-span of the R6/2 model constitute adverse conditions
to detect potentially delayed treatment effects, significant technical hurdles, such as poor cell survival and
differentiation, were also sub-optimal. Further consideration of these aspects is therefore needed in more enduring
transgenic HD models to provide a definite assessment of this cell line’s therapeutic relevance. However, a
combination of treatments is likely needed to affect outcome in transgenic models of HD.
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Despite very significant advances in understanding the
causes of Huntington’s disease (HD), an efficacious ther-
apy remains elusive [1]. Cell therapy is a putative treat-
ment for HD that could slow down neurodegeneration,
replace lost cells and potentially provide a long-term
benefit. Preclinical and proof-of-principle clinical trials* Correspondence: modomm@upmc.edu
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distribution, and reproduction in any mediumusing fetal tissue grafts suggest that therapeutic benefits
are possible [2-4]. However, the usage of human fetal tis-
sue grafts raises several ethical, logistical, and safety con-
cerns. Notably, the procurement of large quantities of
human fetal tissue at an appropriate developmental stage
from elective abortions, establishing the absence of gen-
etic disease or any other potentially harmful contamina-
tions, as well as the heterogeneous (multiple donors)
nature of the grafts, limit their potential usage in a rou-
tine clinical setting [5].
During the last decade, neural stem cell lines emerged
as a potential alternative to fetal tissue grafts, as theyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Composition of cell culture media to expand the
STROC05 cell line
Component Concentration Supplier
DMEM: F:12 Base media Gibco
Human albumin solution 0.03% Baxter
Human insulin 5 μg/ml Sigma
L-glutamine 2 mM Sigma
Putrescine DiHCl 16.2 μg/ml Sigma
Sodium Selenite 40 ng/ml Sigma
L-Thyroxine (T4) 400 ng/ml Sigma
Tri-iodo-thyronine (T3) 337 ng/ml Sigma
Progesterone 60 ng/ml Sigma
Corticosterone 20 μg/ml Sigma
*bFGF-2 10 μg/ml PeproTch
*EGF 10 μg/ml Invitrogen
*4-OHT-tamoxifen 100nM/ml Sigma
Factors with a * were removed to induce a spontaneous differentiation of cells.
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stem cells (hNSCs) afford a sustainable and scalable
homogenous cell source to treat large cohorts of patients
[6]. There is evidence that cell therapy can slow down
neurodegeneration and ameliorate behaviour in rat mod-
els of Huntington’s disease [2,7-9]. Replacement of lost
cells is, however, a greater challenge. Although human
neural stem cells can differentiate into neurons after im-
plantation [10,11], improvements of functional deficits
by fetal striatal transplants into a lesioned rat striatum is
associated with DARPP-32 neurons within the trans-
plants [12-14]. Despite good survival and differentiation
of human neurons in the rats, differentiation of cells into
DARPP-32 neurons remains a challenge [10,15]. Pre-
differentiation of cells prior to implantation into a
DARPP-32 phenotype therefore could potentially result
in an improved outcome [16]. Proof-of-principle of this
strategy for mouse embryonic and neural stem cells have
previously been demonstrated in rat or mouse excito-
toxic models of HD [9,17].
However, to successfully progress this approach to a
routine clinical application, it is essential to develop this
approach for human stem cells [18]. hNSC lines, such as
the STROC05 cell line (derived from the ganglionic emi-
nence of a 12 week-old fetus) have the potential to differ-
entiate in vitro into DARPP-32 cells [19,20] and
potentially could provide a source of pre-differentiated
DARPP-32 neurons for implantation. Ideally the potential
efficacy of either undifferentiated or pre-differentiated
cells is evaluated in a genetic model that exhibits a pro-
gressive phenotype resembling that of human HD. One of
these models, the R6/2 transgenic mouse model
(expresses the exon1 of the human HD gene), is most
commonly used to screen new therapies for Huntington’s
disease [21]. The impact of undifferentiated and pre-
differentiated STROC05 cells on behavioural impairments
and brain atrophy was therefore evaluated in the R6/2
mouse model of Huntington’s disease.
Methods
Human neural stem cell line (STROC05)
The cmyc-ERTAM conditionally immortalized human
striatal neural stem cell line (STROC05, kindly provided
by ReNeuron Ltd., Surrey, UK) was previously described
[19]. In brief, STROC05 cells were isolated from the
whole ganglionic eminence of 12-weeks-old human fetal
brain. The cmyc-ERTAM gene was transfected into cells
with the retroviral vector pLNCX-2 (Clontech). Trans-
fected cell colonies were isolated following neomycin se-
lection before being expanded into a clonal cell line [22].
To maintain proliferation through the conditional
immortalization gene, 4-hydroxy-tamoxifen (4-OHT, 100
nM/ml; Sigma-Aldrich, UK) was added to proliferation
media. The STROC05 cell line was expanded in T75tissue culture flasks (Falcon, UK). Flasks were coated
with mouse laminin at a concentration of 1:100 (mouse,
10 μg/ml; Trevigen, USA) for at least 2 hours at 37°C.
Medium was changed every 2 days and cells were pas-
saged at 90% confluence. The expansion media consisted
of Dulbecco’s Modified Eagle’s Medium/Ham’s F12
(DMEM:F12; Gibco, UK) which was supplemented with
additional components (Table 1). To stimulate prolifera-
tion, growth factors, such as basic fibroblast growth
factor-2 (bFGF-2, 10 ng/ml; Peprotech, UK) and epider-
mal growth factor (EGF, 20 ng/ml; Peprotech, UK), were
added to the media.
In vitro differentiation of STROC05 cells
To induce neuronal differentiation and increase the pro-
portion of DARPP-32 cells, STROC05 cells were grown
in vitro for 21 days on laminin (mouse, 10 μg/ml, Trevigen)
and poly-l-lysine (PLL, 100 μg/ml, Sigma) coated T175
flasks with 90% confluence, as previously described [20].
For the first week, differentiation was induced using media
that contained all components from the proliferation
media, with the exception of bFGF-2, EGF and 6-OHT.
For the 2nd and 3rd week of differentiation, media consisted
of neurobasal media (Gibco) supplemented with B-27
(Gibco), L-Glutamate (Sigma) and Purmorphamine. For
the 2nd week of differentiation, bFGF was added again to
the media as a survival factor [23] and to promote a rostral
positional specification of neurons [24,25], but was omitted
again for the 3rd week of differentiation as positional speci-
fication in most cells is completed. Purmorphamine (1 μM,
Calbiochem) was added to the culture media throughout
the 3 weeks of differentiation.
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As differentiated cells are very vulnerable when removed
from tissue culture flasks, it is essential to establish
whether harvesting these cells after long-term differenti-
ation affects their viability and differentiation status. For
this, cells were harvested with Trypzean EDTA for less
than five minutes at 37°C, followed by adding a soybean
trypsin inhibitor to inactivate the enzymatic activity.
After harvesting, cells were centrifuged for 5 minutes at
1500 rpm and the cell pellet was re-suspended in 1 ml
of DMEM. Using the trypan blue exclusion test, cells
were counted and viability was established to be 89.5%.
Cells were re-seeded on laminin-coated cover slips in 24
well plates at 100,000 cells per well. After 24 h, viability
of these re-seeded conditions was evaluated again using
the live/dead stain (viability/cytotoxicity kit for mamma-
lian cells, Gibco) and compared to cells that were not
harvested. For the live/dead stain, media was aspirated
and cells were washed once with PBS prior to incubation
with 2 μM calceinAM (to detect live cells) and 4 μM
ethidium homodimer-1 (EthD-1) (to detect dead cells) in
PBS (500 μL per well) for 45 minutes at 37°C. Photos
were taken immediately using a fluorescent microscope
(Zeiss). A separate set of coverslips were fixed with 4%
Parafix (Pioneer) for 5 min. Immunohistochemistry was
used to establish if harvesting of cells would affect the
proportion of neurons (1:500, mouse anti-β-III-tubulin,
Tuj, AB7751, Abcam) and specifically DARPP-32 neu-
rons (1:500, rabbit anti-DARPP-32, AB1656, Chemicon)
within the cell suspension. After overnight incubation
(at room temperature) with the primary antibody, an ap-
propriate secondary ALEXA594 (1:1000, Molecular
Probes) was applied for 60 min prior to attaching the
coverslips to microscopic slides with Vectashield for
fluorescence containing DAPI (Vector Laboratories).
Total DAPI, as well as Tuj and DARPP-32 cells, were
counted under a Zeiss Axioscope.
R6/2 mice
All procedures of this study were carried out according
to the UK Animals (Scientific procedures) Act 1986
(PPL70/6445), as well as the ethical review process of
King’s College London. A widely used and well charac-
terized mouse transgenic model of Huntington’s disease,
R6/2 mice present with a rapid disease onset that is evi-
dent as early as 6 weeks of age. Especially the develop-
ment of a clear behavioural phenotype in the R6/2
compared to the N171-82Q or HDH111 is important to
establish a potential therapeutic efficacy.
The average life span of R6/2 mice with 210 CAG
repeats is approximately 16 weeks of age [26]. Here, R6/2
mice were generated from a colony that was maintained
by backcrossing R6/2 males to (CBA × C57BL/6) F1
females (B6CBAF1/OlaHsd, Harlan, UK). Mice werekept in standard housing conditions, on a standard
chow diet with water available ad libitum. During the
last 2 weeks of the study (12 and 13 weeks of age), a
mash diet was prepared by soaking chow pellets in
water. These were placed in the floor of the cages within
easy reach of the motor impaired R6/2 mice. Transgenic
mice were identified by Polymerase Chain Reaction
(PCR) on an ear tissue sample at 4 weeks of age, as pre-
viously described [27].
Forty female mice were randomized into 4 groups;
wild type mice receiving vehicle (WT-veh, n = 10), R6/2
mice receiving vehicle (R6/2-veh, n = 10), R6/2 mice
receiving undifferentiated cells (R6/2-undiff, n = 10),
and R6/2 mice receiving long-term purmorphamine-
differentiated cells STROC05 (R6/2-diff, n = 10). Mice
were group-housed 4 per cage containing mixed ge-
notypes (one from each experimental group) to ensure
comparable standard housing conditions, as described
by Hockley et al. [26].
Cell implantation
On the day of transplantation, the cells were harvested by
incubation with Trypzean EDTA for less than five minutes
at 37°C, followed by adding soybean trypsin inhibitor to
inactivate the enzymatic activity. After harvesting, cells
were centrifuged for 5 minutes at 1500 rpm and the cell
pellet was re-suspended in 2 ml of DMEM for cell count-
ing. Cells were suspended in vehicle consisting of 2.5 ml of
DMEM and 3.75 ml of Hypothermosol (BioLife Solutions)
at a concentration of 7.5 × 104 cells/μl. Using the trypan
blue exclusion test, viability was determined to be 89%.
At 7 weeks of age, mice underwent stereotactic sur-
gery for the injection of NSCs. This allowed sufficient
time to conduct pre-implantation MRI scans, as well as
behavioural test, after animals were weaned at 4 weeks
of age from their mothers. Additionally, animals’ geno-
type was determined and animals were randomly allo-
cated to their experimental groups based on a sequence
of random numbers. Although at 7 weeks of age, R6/2
mice do not exhibit a motor deficit [28], they do never-
theless already show signs of brain atrophy [29]. Impor-
tantly, R6/2 mice do not display any neuronal loss [28].
At this age, there is also a decrease, as well as morpho-
logical abnormalities, in microglia [30].
For cell implantation, anaesthesia was induced through
isoflurane inhalation (Abbott) at 4-5%, then maintained at
1.5-2%. Animals were mounted in a stereotaxic frame and
a sagittal incision was carefully made followed by the dril-
ling of two burr holes. Either 6 μl (3 μl per side, 0.5 μl/min)
of cells or vehicle were injected with a 22 Gauge needle
attached to 10 μl Hamilton syringe using a convection-
enhanced delivery [31] at Anterior-Posterior +0.5 mm
(in relation to Bregma), Lateral ±2 mm and −3.5 mm below
the surface of the dura. The deposit was divided into two
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of the needle by 0.5 mm) and the other at −2.5 mm. After
injection, the syringe was left in place for 5 minutes and
slowly withdrawn over 3 minutes, followed by suturing
of the incision. During the surgery, body temperature
was controlled using a homeostatic heating pad set at
37°C. No immunosuppression was given as STROC05
cells exhibit a robust survival in the 3-nitropropionic
acid rat model of Huntington’s disease over 90 days
(Additional file 1: Figure S1), as well as wild-type mice
(Additional file 2: Figure S2).
After surgery, post-operative care included fluid-replacement
(0.1 ml saline/animal) and a local analgesic (EMLA cream 5%;
AstraZeneca, UK). The animals were singly caged with
softened food pellets and water available ad libitum
for 24 h before being returned to their home cages.
Body weight
Weight loss is a prominent symptom in R6/2 mice
[28,32]. Body weight has often been used as a reliable
outcome measure to assess the beneficial effect of differ-
ent therapeutic approaches in R6/2 mice [26,33-37].
Mice were weighted weekly from the time of weaning
(4 weeks) until the end of the study. To avoid the impact
of diurnal feeding habits, body weight was obtained
weekly on the same day and time.
Behavioural battery
For each behavioural test, the running order of animals
was based on a randomization of the cages, but within
each cage (containing WT and R6/2), mice were run se-
quentially. Animals within each cage were randomly
chosen for each trial. If more than one trial was con-
ducted, this was run in the same sequence.
Rotarod
The rotarod is considered a very sensitive and reliable
motor task to assess motor coordination in HD trans-
genic mice [26,38]. R6/2 mice are known to have
impaired rotarod performance [39,40]. According to a
standard protocol [26], mice were placed on a rotarod
(Ugo Basile) with a 3 cm diameter rod at a constant
speed of 4 rpm for 20 sec. After this acclimatisation
period, the rod speed accelerated from 4 to 40 rpm over
300 sec. Latency for mice to fall from the rod was
recorded. Rotarod performance was assessed over three
successive days with 3 trials per day. The first assess-
ment day was always excluded from analysis. Mice were
tested one week pre-transplantation, as well as at 1, 3,
and 5 weeks post-transplantation.
Open field
The open field test has been used extensively as a reli-
able measure to evaluate locomotor activity and anxiety-like behaviour in R6/2 mice [41,42]. A custom-built
100 cm diameter and 35 cm deep circular open field arena
(Engineering & Design Plastics) was divided into outer
and inner zones by a circle drawn 4 cm from the outer
walls. Mice were placed individually in the outer zone
facing the centre of the maze with their behaviour being
automatically recorded by a camera for a period of 5 min.
Data was subsequently analysed using Ethovision XT7.0
software (Noldus). The arena was cleaned between mice to
prevent behavioural influences from the odours of previous
trials. Total distance travelled (locomotion) and time spent
in the outer zone (thigmotaxis, indicative of anxiety-like
behaviour) were measured one week pre-transplantation, as
well as at 1, 3, and 5 weeks post-transplantation.
Grip strength
Grip strength analysis is a reliable and sensitive test to
evaluate muscular strength in R6/2 mice [26,39,42]. To
measure forelimb grip strength, mice were lowered
towards the grid to grab it with both front paws. Mice
were gently pulled back until they released their grip and
the equipment automatically measured the force required
to pry the mouse from the grid. A single session consisting
of 5 consecutive trials was recorded once a week at 4, 5,
and 6 weeks post-grafting. As low scores may be due to
the mouse failing to grip the grid effectively, the best three
scores of the five trials were averaged.
Magnetic Resonance Imaging (MRI)
Six weeks following cell implantation, mice were anesthe-
tised using isoflurane (4-5% induction, 1.5-2% maintenance
in 0.7 l/min medical air and 0.3 l/min oxygen) and fixed
within a head holder/respiration mask to reduce head
movement. MR images were acquired using a 7 Tesla mag-
net (Varian), equipped with a 100 Gauss gradient set and a
39 mm transmission/receive coil (Rapid). A T2-weighted
multi-echo multi-slice (MEMS) sequence was used
(TR=2500 ms, minimum TE=10 ms, number of echo=8,
echo spacing=10 ms, averages = 4, matrix = 128x128, and
FOV=20 × 20 mm). Thirty coronal slices with 0.5 mm
thickness were acquired across the mouse brain. Manual
segmentation of anatomical regions of interest (ROIs,
Additional file 3: Figure S3), including whole brain, stri-
atum, cortex, hippocampus, and lateral ventricle, was per-
formed using JIM 5.0 (Xinapse). Criteria used to define
ROIs are summarized in Table 2. Manual segmentation of
the same structure at two separate occasions yielded an
intra-rater discrepancy of less than 2% error.
Immunohistochemistry
After MRI scanning, anesthetized animals received an
intracardial perfusion of saline followed by 4% Parafix
(Pioneer). Brains were excised and post-fixed for 24 h at
6°C before being cryoprotected in 30% sucrose at 6°C.
Table 2 Anatomical criteria adopted to manually segment
ROIs
Brain regions Anatomical boundaries for regions of
interest (ROIs)
Whole brain Anterior - the first slide behind the eye sacs
Posterior - the first slide where the hemispheres
disappear
Lateral ventricle Hyperintense T2 signal of the cerebrospinal fluid
Striatum Dorsal - corpus callosum
Lateral - external capsule
Medial - lateral ventricle
Ventral - anterior commissure
Cortex Internal - corpus callosum & vertical line from
lateral edge
External - skull
Inferior - horizontal line from anterior commissure
Hippocampus External - corpus callosum
Internal - external capsule
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tome in the coronal plane and stored at −20°C in tissue
cryoprotective solution (25% glycerine, 30% ethylene gly-
col, and 50% PBS).
To identify transplanted cells, sections were stained
with a mouse anti-human nuclear protein (HNA) anti-
body (1:400, MAB1218, Millipore). For this, sections
were rinsed with PBS, blocked for 30 minutes in
0.1%H202 as inhibitor for endogenous peroxidase activ-
ity (Sigma), followed by 60 min incubation in 10%
blocking solution (10% normal goat serum in 0.3%
Triton X-100 PBS) at room temperature (RT, 21°C). To
block the non-specific binding of endogenous biotin, the
sections were incubated with avidin-biotin blocking
solutions (Vector) for 30 min. The sections were incu-
bated with the HNA antibody at RT for an hour, fol-
lowed by 10 min of incubation at RT with secondary
biotinylated anti-mouse antibody (1:200, Vector), and
5 min at RT with an avidin-biotinylated-peroxidase com-
plex (1:100 in PBS, Vector). Secondary antibody binding
was visualized using 3,3’-diaminobenzoic acid (DAB,
Sigma) dissolved in PBS with the addition of H202 to a
concentration of 0.03% immediately before use. Finally,
the sections were washed in PBS, mounted onto glass
slides, dehydrated for 5 min in each of 70, 85, 90, and
100% alcohol, cleared by xylene, and coverslipped with
Entellen (Merck, UK).
For fluorescence immunohistochemistry, sections were
incubated for 60 min in 10% blocking solution (10% nor-
mal goat serum in 0.3% Triton X-100 in PBS) at RT, fol-
lowed by 30 min of an avidin-biotin blocking solution
(Vector). Sections were then incubated with appropriate
primary antibodies against transplanted cells (mouseanti-HNA 1:400), neurons (rabbit anti-Fox3, 1:500,
ab104225, Abcam), or DARPP-32 neurons (rabbit anti-
DARPP-32, 1:500). After overnight incubation with the
primaries, an appropriate secondary antibody (1:200,
ALEXA 350; 1:500, ALEXA 647, Molecular Probes) was
applied for 60 minutes at RT. Sections were rinsed in
PBS and mounted in Vectashield with DAPI.
Statistical analyses
Statistical analyses were conducted using GraphPad
Prism 5.03 (GraphPad Software, San Diego, California,
USA) to determine significant differences (p < .05)
between in vitro and post-mortem immunohistochemis-
try (independent samples t-test), as well in vivo measures
(repeated-measures two-way ANOVA). Bonferroni post-
hoc tests were applied if ANOVAs revealed a significant
result. All error bars on graphs are displayed as the
standard error of the mean (SEM).
Results
Differentiated cells retain viability and DARPP-32
phenotype after harvesting and re-seeding
To assess whether transplantation of long-term differen-
tiated cells is possible, long-term differentiated cultures
were harvested and reseeded to measure potential effects
on viability and neuronal differentiation. Viability
straight after harvesting of differentiated cells was above
90% as indicated by the trypan blue exclusion test. This
good viability was maintained after re-seeding these cells
for 24 h (Figure 1A). The harvesting re-seeding proced-
ure also did not reduce the neuronal population
(Figure 1B). The number of β–III-tubulin- and DARPP-
32-positive cells remained fairly consistent (Figure 1C).
The number and percentage of astrocytes also was con-
sistent between pre-harvesting conditions and re-
seeding (Figure 1D). These results suggest that the
harvesting re-seeding process did not significantly
affect the viability of differentiated cells and the
neuronal population is very similar to the pre-harvest
condition.
Cell implants do not impact on weight loss
Body weight is a reliable indicator of the overall health
of R6/2 mice. The body weight of wild type (WT) and
R6/2 mice (n = 10/genotype) steadily increased until
8 weeks of age (1 week post-implantation, Figure 2),
after which they cease to gain weight. By 3 weeks post-
implantation, R6/2 mice had significantly lower body
weight compared to WT mice. Animals that received
undifferentiated or differentiated cells followed the
same weight pattern than those R6/2 mice that
received a vehicle injection. These results suggest
that cell implantation did not impact on weight loss in
R6/2 mice.
Figure 1 Viability and neuronal phenotype of re-seeded cultures. Harvesting and re-seeding of long-term differentiated cultures did not
significantly affect their viability (A, Live/Dead stain), neuronal differentiation (B,β-III-tubulin, Tuj), DARPP-32 (C), or astrocytic differentiation (D).
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behavioural deficits
The development of a progressive behavioural pheno-
type is a key characteristic of R6/2 mice. Up to 8 weeks
of age (1 week post-implantation), the R6/2 animals per-
formed as well as WT controls on the rotarod
(Figure 3A), but gradually thereafter their rotarod per-
formance deteriorated as compared to WT controls. Im-
plantation of cells (undifferentiated or differentiated) did
not prevent this deterioration. A significant locomotor
deficit was already evident in R6/2 animals pre-
implanted at 7 weeks of age (Figure 3B). This deficit
gradually worsened and the cell therapy had no signifi-
cant impact. There was also no significant alteration inanxiety-like thigmotaxis behaviour in the R6/2 mice
(data not shown). Grip strength was consistently
impaired in the animals between 4 and 6 weeks post-
grafting, and no improvement due to cell implantation
was evident (Figure 3C). Therefore, neither the bilateral
implantation of undifferentiated, nor differentiated cells
significantly impacted on the emergence or the progres-
sion of clear behavioural deficits in the R6/2 mouse
model of Huntington’s disease.
Cell implants did not reduce brain atrophy
To determine whether cell implants reduced the brain
atrophy of R6/2 mice compared to WT controls,
T2-weighted MRI scans were acquired 6 weeks post-
Figure 2 Body weight. Weight gain between groups was
equivalent up to 7 weeks of age when animals were grafted. Post-
implantation WT mice with vehicle injection continued to gain
weight. All R6/2 mice started to lose weight 3 weeks post-grafting
(11 weeks of age). There was no effect of the implantation of
undifferentiated or differentiated cells on body weight.
Figure 3 Behaviour. A. Rotarod: no effect of genotype on rotarod
performance was detected one week pre- or post-grafting. However, a
significant impairment was evident in R6/2 mice at 3 and 5 weeks post-
grafting which was not improved through the implantation of
undifferentiated or differentiated cells. B. Open field: the total exploratory
activity of R6/2 was reduced compared to WT controls at all time points
tested. Neither undifferentiated, nor differentiated, cells attenuated the
deterioration of R6/2 exploratory behaviour.
C. Grip strength: all R6/2 mice showed significantly impaired
performance compared to WT mice at all time points. No beneficial
effect of treatment was evident. (* p<0.05, **p<0.01, and ***p<0.001).
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hicle, undifferentiated or differentiated exhibited similar
levels of atrophy in the striatum (Figure 4A), cortex
(Figure 4B) and hippocampus (Figure 4C). Ventricular
volume was comparable to WT animals (Figure 4D).
Therefore there was no evidence to support a neuropro-
tective effect of cell implantation.
Survival and differentiation of cell implants
The survival and differentiation of the implanted cells
are essential to guarantee a potentially beneficial effect.
Post-mortem immunohistochemical analyses 6 weeks
post-implantation indicated that in 70% of R6/2-undiff
and 50% of R6/2-diff animals some STROC05 cells sur-
vived six weeks post-implantation. A re-analysis of the
behaviour and MRI results indicated that exclusion of
animals without surviving cells did not significantly
affect outcome (Additional file 4: Figure S4). Surviving
cells were mostly confined to the injection tract
(Figure 5A), with a select few showing a limited migra-
tion in the corpus callosum. In the left hemisphere of
R6/2-undiff mice, only 161.2 ± 46.8 STROC05 cells sur-
vived, whereas 81.9 ± 34.16 cells survived in R6/2-diff
animals (Figure 5B). However, given the wide variabil-
ity within each group, a statistically significant differ-
ence between these two types of implants in terms of
cell survival could not be detected. Despite the gener-
ally poor cell survival, a small number of STROC05
cells expressed Fox3 in both the R/6-undiff (1.2%) and
R6/2-diff (2%) conditions (Figure 5C&D). DARPP-32
was not detected in any of the implanted cells. Almost
all implanted cells were GFAP-positive (Figure 5E)
Figure 4 MRI. Volumetric analysis revealed a significant atrophy in striatal (A), cortical (B), and hippocampal tissue (C). Lateral ventricles (D) were
minimally enlarged, but no significant statistical effect was evident. There was no treatment effect of the implantation of either undifferentiated
or differentiated cells. (* p < 0.05, **p < 0.01, and ***p < 0.001).
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whereas neurons did not. Therefore, most implanted
cells did not survive by 6 weeks post-implantation and
pre-differentiation of STROC05 cells did not increase
the presence of neuronal cells post-grafting.
Discussion
Cell therapy for Huntington’s disease is potentially an
important intervention to delay, stabilize and/or improve
impairments. These therapeutic effects are well docu-
mented in animal models, but more limited, albeit posi-
tive, evidence is available in patients with Huntington’s
disease that received fetal tissue transplants [43]. However,
in the present study, the STROC05 human neural stem cell
line in the R6/2 mouse model of HD did not promote re-
covery. It is important to recognize that a multitude of
requirements need to be met for this therapy to be success-
ful and several explanations need to be considered to ac-
count for our results: 1) STROC05 cells are not efficacious
in HD, 2) insufficient cells survived to promote recovery,
3) there was an insufficient neuronal/DARPP-32 differenti-
ation of cells, and 4) it is also conceivable that the R6/2
model might be too aggressive to evaluate hNSC as a
restorative treatment.
Lack of efficacy and poor cell survival
Therapeutic efficacy in Huntington’s disease is considered to
be associated with a decrease in neurodegeneration, as wellas a replacement of lost striatal DARPP-32+ GABAergic
output neurons. An intra-striatal injection of fetal-derived
neural progenitors/stem cells [2,13], NSC lines [7,8], as well
as mesenchymal cells [44] produces an improvement in be-
havioural impairment. Even an intravenous injection of mes-
enchymal cells can achieve improvements in Huntington’s
disease with only a small fraction of cells penetrating the
brain [45]. However, human neural stem cells from the
STROC05 neural stem cell line did not improve outcome in
the R6/2 mouse model of HD.
It is therefore important to consider why STROC05
cells did not improve outcome. Foremost of all, survival
of cells after implantation was rather poor with only 161
human cells surviving in one hemisphere. Although
there have been reports of behavioural changes with 124
cells surviving in stroke [46], most efficacious studies
using cell implantation in Huntington’s disease report
survival rates of 2 × 104 cells [2]. Interestingly, STROC05
survival in the 3NPA rat model of HD resulted in
2.5 × 104 cells surviving at 3 months. It is therefore
conceivable that either the progressive pathology or the
mouse host are factors that affect the long-term survival
of these cells. Improving cell survival in a mouse host will
be key to establishing whether the poor cell survival is the
reason for the lack of efficacy. While there was no
evidence here of graft rejection, it is conceivable that an
early immune response could have affected cell survival
and hence efficacy. If this were the case, administration
Figure 5 Survival of the transplanted cells. A small population of implanted cells survived (A). Human cells (human nuclear antigen+ cells in
pink) were mostly found within the injection tract in the striatum. A select few individual cells were observed migrating along the corpus
callosum. Stereological cell counts revealed no significant difference between undifferentiated and differentiated cell implantation (B). However,
cell survival was very variable with some animals having no surviving cells. Neuronal differentiation, as determined by FOX3 staining, of implanted
cells was very poor (C&D). Most implanted cells differentiated into astrocytes (E), whereas others did neither express markers of neurons nor
astrocytes. (Scale bar 200 μM).
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ment would be expected to improve graft survival
and potentially provide sufficient cell survival to promote
recovery.
Although the survival of cells is thought to be essential
to establish recovery by means of intracerebral hNSC
implantation, the lack of differentiation of STROC05
cells might also preclude recovery. Especially, the differ-
entiation of cells into striatal DARPP-32+ GABAergic
output neurons has been considered to be directly linked
to the degree of functional recovery [47,48]. One
approach to increase the number of DARPP-32+ neuronsfrom implanted cells is to direct their differentiation prior
to injection. This can either be achieved using chemical
factors or genetic engineering [9,18,20,49]. Although the
hedgehog agonist purmorphamine here increased the dif-
ferentiation of STROC05 cells into DARPP-32+ neurons
over 3 weeks in vitro without affecting viability when these
cells are re-suspended, none of the cells had survived for
6 weeks post-implantation. It is conceivable that this is a
reflection of the overall poor survival of cells, but it would
be reasonable to expect that some improvement in neu-
ronal survival of implanted cells could be expected after
implantation of pre-differentiated cells. Nevertheless, this
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ation in the undifferentiated and differentiated cell groups.
This is in stark contrast to other reports where pre-
differentiated cells exhibited good survival with an im-
provement in the survival of DARPP-32 cells [9,18,49].
There is indeed evidence that pre-differentiation of cells
makes them especially vulnerable to apoptosis [50].
Improving overall cell survival might therefore also poten-
tially increase the survival of pre-differentiated cells,
but as in Parkinson’s disease additional survival factors
(e.g. BDNF, GDNF) might be required to ensure the long-
term survival and integration of these neurons [51,52].
Apart from poor cell survival and differentiation, it is
plausible that, even if these issues are overcome, this cell
line is not efficacious in Huntington’s disease. If this
would indeed be the case, this cell line would provide an
indispensable “therapeutic control” condition against
which mechanisms of efficacious cells could be com-
pared. Nevertheless, it is also conceivable that this cell
line could provide efficacious results if implanted under
different experimental conditions.
Choosing an appropriate animal model of Huntington’s
disease
STROC05 cells might be efficacious for Huntington’s
disease, but it is possible that testing them in the R6/2
model does not reflect their therapeutic potential. The
R6/2 model rapidly manifests behavioural impairments,
as well as regional brain atrophy. This rapid progression
of disease might be appropriate for screening pharmaco-
logical agents that exert immediate effects, but the time
window might be too short and aggressive to evaluate
the efficacy of neural progenitor/stem cells. Mouse mod-
els that develop neuronal loss over a protracted time
course, such as the YAC72 [53] or HDH(CAG)150 [54]
might hence provide more appropriate conditions to
establish the therapeutic efficacy of intracerebral cell
implantation. Neural progenitor/stem cell implantation
typically takes several weeks before therapeutic effects
are evident. Therefore when R6/2 mice are almost mori-
bund, implanted cells are expected to exert their effect
and the disease might have progressed too far at this
stage for any efficacy to be apparent. Additionally, the
progression of the disease could impact on the cell’s sur-
vival [55]. Similar observations were evident in a previ-
ous study in R6/2 mice using fetal primary tissue grafts,
where there was sufficient graft survival, but no mean-
ingful therapeutic efficacy [56], although the same type of
graft provided a significant improvement in neurotoxin-
induced lesions modelling Huntington’s disease [13]. A
similar difference in behavioural recovery between neuro-
toxic lesions in the mouse and the R6/2 were also
observed after an intrastriatal injection of mesenchymal
stem cells [57]. Merely implanting neural progenitor/stemcells in transgenic mice might hence be insufficient to
achieve therapeutic efficacy.
A combination of treatments for various aspects of the
disease might be needed for implanted cells to be
efficacious. For instance, an injection of only mouse
neural progenitors did not maintain motor function in
N171-82Q transgenic mice, but if these same progenitors
were engineered to also secrete GDNF, they provided a
therapeutic benefit [58]. In the R6/2 mice, therapeutic ef-
ficacy was also achieved with NSCs, but only if these
were administered in conjunction with a retardation of
CAG aggregate formation using trehalose [59]. Trans-
genic mice therefore are likely to be appropriate models
for establishing therapeutic efficacy in Huntington’s dis-
ease, but a combinatorial approach that concurrently
impacts on different disease mechanisms might be
needed to progress cell implantation as a treatment strat-
egy. Having to target multiple mechanisms of the disease,
as well as supplying novel cells to the brain, are likely to
be a better reflection of the clinical condition than
expecting neural progenitor/stem cells to be sufficiently
efficacious to avert a further deterioration of patients.Conclusions
Neither the implantation of undifferentiated, nor pre-
differentiated human NSCs promoted behavioural benefits
or attenuated the on-going neurodegenerative process.
This is likely due to a combination of factors, most im-
portantly cell survival was insufficient to impact on the
progression of the disease, but the life-span of R6/2
mice might also be too short to appropriately evaluate
neural progenitors/stem cells. More chronic transgenic
models are likely to be better in evaluating these ther-
apies. However, implantation of cells by themselves is
unlikely to be sufficiently efficacious to promote recov-
ery, but rather a combination of multiple treatments
will be required to provide a truly efficacious therapy
that can impact on the clinical condition.Additional files
Additional file 1: Figure S1. STROC05 survival in the
3-nitroproprionic acid (3-NPA) rat model of Huntington’s disease. Male
Lewis rats (220-250 g) received i.p. injections of 42 mg/kg 3-NPA.
(Sigma-Aldrich) for five consecutive days to induce a bilateral
degeneration of striatal cells, as previously described [8]. Animals
gradually develop a behavioural phenotype and show a progressive
striatal tissue loss that coincides with neuronal loss, as well as an increase
in glial scarring and microglia activity [8]. Additionally, these animals
show a clear deficit in brain activity [7,60]. Two weeks after lesion
induction, animals received unilateral injections of 400,000 STROC05
human neural stem cells (hNSCs). hNSCs can be detected in the injection
tract using human nuclear antigen (A). The presence of
CD11b+microglia reveals the inflammatory response to the ongoing
neurodegeneration in the lateral striatum and indicates a placement of
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http://www.biomedcentral.com/1471-2202/13/97cells just peripheral to the damage. Higher magnification images reveal a
limited migration from the injection tract to the area of damage (B&C).
STROC05 cells retained some expression of nestin (D&E), but also partially
differentiated into GFAP+ astrocytes. Using brightfield microscopy of cell
survival (G) in animals that were either immunocompetent or
immunosuppressed using Cyclosporine A (CsA, Sandimmun, Novartis,
10 mg/kg, diluted in Ringer’s solution) and methylpredinolone (20 mg/
kg day 1–7; 10 mg/kg day 8–12; 5 mg/kg day 13–14 i.p., Pharmacia
Upjohn), a sterelogical analysis indicated a robust cell survival under both
conditions over 90 days. Over 10,000 cells survived in the
immunocompetent group and 25,000 cells were present in the
immunosuppressed rats. It was only at 90 days survival that there was a
significant difference between immunosuppression and
immunocompetent animals (* P < .05), but there was no significant
decrease in cell number between 30 and 90 days. Discontinuation of
immunosuppression also did not lead to a graft rejection.
Additional file 2: Figure S2. Acute survival of STROC05 in WT mice. An
injection of 225,000 STROC05 cells in 3 μl (75,000 cells/μl) at 7 weeks of
age into wild-type mice resulted in a good graft survival (Human nuclei
antigen, HNA, in red, DAPI in blue), even in the absence of
immunosuppression. Cells remained within the injection tract and did
not exhibit any migration out of their site of injection. To ensure a better
distribution of cells within the striatum, two deposits were placed within
the same injection tract. A glial reaction (GFAP + cells in green) was
evident along the injection tract. These results indicate that STROC05
cells can survive in WT animals and that using this protocol there is a
robust engraftment.
Additional file 3: Figure S3. Representative T2x-weighted MRI images.
Images illustrated the anatomical boundaries used to define regions of
interests corresponding to anatomical structures (red lines).
Additional file 4: Figure S4. Re-analysis of the main outcome
measures. As some animals had no graft survival, it is conceivable that
this would affect the group outcome measure. Therefore we reanalysed
the data excluding these animals. The analysis containing all animals is
presented on the left and the reanalysed data on the right. Exclusion of
animals without graft survival, however, did not make a difference to
these results.
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